An Investigational Study of Cyclosporine on Experimental Medication BMS-986165 in Healthy Male Participants

Bristol-Myers Squibb (BMS)

Status and phase

Completed

Phase 1

Conditions

Psoriasis

Treatments

Drug: Cyclosporine

Drug: BMS-986165

Study type

Interventional

Funder types

Industry

Identifiers

IM011-045

Details and patient eligibility

About

This is an investigational study of Cyclosporine on the experimental medication BMS-986165 in healthy male participants.

Enrollment

54 patients

Sex

Male

Ages

18 to 50 years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

Healthy participant, as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations
Body mass index 18.0 to 32.0 kg/m2
Weight ≥ 50 kg

Exclusion Criteria:

Any medical condition that presents a potential risk to the subject and/or may compromise the objectives of the study, including a history of or active liver disease
History or presence of acute or chronic bacterial, fungal, or viral infection (eg, pneumonia, septicemia) within the 3 months prior to screening
Known or suspected autoimmune disorder, or any history of known or suspected congenital or acquired immunodeficiency state or condition that would compromise the participant's immune status
History of administration of live vaccines within 60 days before screening
Any history or risk for tuberculosis (TB)

Other protocol defined inclusion/exclusion criteria could apply